For the Inventor, By the Inventor

Enter assignee name

San Diego, CA, United States of America

Amylin Pharmaceuticals, Inc.

USPTO Granted Patents = 164

CIPO Patents = 7

EPO Patents = 42

Trademarks = 8

Forward Citations = 4,934

Loading Chart...

Loading Chart...

155 inventors (with patents filed for the assignee):

Andrew A Young (53 out of 68 patents)

Kathryn Susan Prickett (37 out of 38 patents)

Soumitra S Ghosh (21 out of 58 patents)

4. David Geoffrey Parkes (20 out of 21 patents)

5. Christine Marie Mack (16 out of 17 patents)

6. Nigel Robert Arnold Beeley (15 out of 16 patents)

7. Odile Esther Levy (14 out of 29 patents)

8. Christopher Joseph Soares (13 out of 23 patents)

9. Bronislava Gedulin (13 out of 26 patents)

10. Carolyn M Jodka (13 out of 14 patents)

11. Lawrence J D'Souza (13 out of 14 patents)

12. Michael R Hanley (12 out of 26 patents)

13. Richard A Pittner (11 out of 11 patents)

14. Thomas R Coolidge (11 out of 23 patents)

15. Orville G Kolterman (11 out of 11 patents)

Core Competencies:

Diabetes Treatment

Engineered Polypeptides

GLP-1 Receptor Agonists

Sustained Release Formulations

Exendin Peptides

Hybrid Polypeptides

Amylin Agonists

Drug Delivery Devices

Peptide-Peptidase Inhibitors

Obesity Management

Cardiac Remodeling

Psychiatric Disorders

164 patents: Sort by Forward Citations

1. 9884092 - Methods for treating diabetes and reducing body weight (2018-02-06),

2. 9593154 - Engineered polypeptides having enhanced duration of action (2017-03-14),

3. 9453063 - Hybrid polypeptides with selectable properties (2016-09-27),

4. 9382304 - Engineered polypeptides having enhanced duration of action with reduced immunogenicity (2016-07-05),

5. 9249181 - C-terminal amidation of polypeptides (2016-02-02),

6. 9248240 - Formulation delivery device (2016-02-02),

7. 9238076 - Polymer-based sustained release device (2016-01-19),

8. 9217022 - GLP-1 receptor agonist compounds having stabilized regions (2015-12-22),

9. 9161953 - GLP-1 receptor agonists for islet cell transplantation (2015-10-20),

10. 9133260 - GIP analog and hybrid polypeptides with selectable properties (2015-09-15),

11. 9034819 - Method of lowering cholesterol and triglycerides by administering exendins (2015-05-19),

12. 8951962 - Modified exendins and exendin agonists (2015-02-10),

13. 8946149 - Use of exendin and analogs thereof to delay or prevent cardiac remodeling (2015-02-03),

14. 8927687 - Microcrystalline Y receptor agonists (2015-01-06),

15. 8906851 - Method for treating diabetes (2014-12-09),

Amylin Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines for the treatment of metabolic diseases. With a commitment to improving the lives of people with diabetes and other related conditions, Amylin develops therapies that aim to enhance the management of these diseases and help patients achieve better health outcomes.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

164 Patents

#34 in San Diego, CA

#534 in California

#2,343 in US

#4,899 in the World

San Diego, CA, United States of America

Amylin Pharmaceuticals, Inc.

Forward Citations = 4,934

155 inventors:

Andrew A Young (53 out of 68 patents)

Kathryn Susan Prickett (37 out of 38 patents)

Soumitra S Ghosh (21 out of 58 patents)

4. David Geoffrey Parkes (20 out of 21 patents)

5. Christine Marie Mack (16 out of 17 patents)

Please report any incorrect information to support@idiyas.com

Loading…